Respiratory syncytial virus vaccine - Biologic Drug Details

« Back to Dashboard

Summary for respiratory syncytial virus vaccine

Tradenames:	2
High Confidence Patents:	81
Applicants:	3
BLAs:	3
Suppliers: see list	3
Recent Clinical Trials:	See clinical trials for respiratory syncytial virus vaccine

Recent Clinical Trials for respiratory syncytial virus vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Centre Hospitalier Annecy Genevois	PHASE3
Abogen Biosciences (Shanghai) Co., Ltd	PHASE2
Suzhou Abogen Biosciences Co., Ltd.	PHASE2

See all respiratory syncytial virus vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for respiratory syncytial virus vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for respiratory syncytial virus vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2033-10-14	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2034-07-24	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2036-08-18	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2035-09-16	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for respiratory syncytial virus vaccine Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2033-02-11	Patent claims search

International Patents for respiratory syncytial virus vaccine

Country	Patent Number	Estimated Expiration
Australia	2013331763
Australia	2019358419
Brazil	112021005670
Canada	2883264

Supplementary Protection Certificates for respiratory syncytial virus vaccine

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CA 2026 00014	Denmark		PRODUCT NAME: RSV SUBGROUP A GLYCOPROTEIN F STABILIZED IN THE PREFUSION CONFORMATION; NAT. REG. NO/DATE: EU/1/23/1752 20230824; FIRST REG. NO/DATE: EU EU/1/23/1752. 20230824
202640017	Slovenia		PRODUCT NAME: RSV SUBGROUP A GLYCOPROTEIN F STABILISED IN THE PREFUSION CONFORMATION AND RSV SUBGROUP B GLYCOPROTEIN F STABILISED IN THE PREFUSION CONFORMATION; NATIONAL AUTHORISATION NUMBER: EU/1/23/1752; DATE OF NATIONAL AUTHORISATION: 20230823; AUTHORITY FOR NATIONAL AUTHORISATION: EU
C20260004	Finland
CA 2026 00016	Denmark		PRODUCT NAME: RSV SUBGROUP A GLYCOPROTEIN F STABILIZED IN THE PREFUSION CONFORMATION AND RSV SUBGROUP B GLYCOPROTEIN F STABILIZED IN THE PREFUSION CONFORMATION; REG. NO/DATE: EU/1/23/1752 20230324